Advertisement

Topics

CLDX Disappoints Investors, ASNS Awaits Data In 2H18, BPMC Fails To Make A Mark

00:08 EDT 17 Apr 2018 | RTTNews

Celldex Therapeutics plunged 64% on Monday, following disappointing results from its phase IIb study of Glembatumumab vedotin in patients with metastatic triple negative breast cancers, dubbed METRIC.

Original Article: CLDX Disappoints Investors, ASNS Awaits Data In 2H18, BPMC Fails To Make A Mark

NEXT ARTICLE

More From BioPortfolio on "CLDX Disappoints Investors, ASNS Awaits Data In 2H18, BPMC Fails To Make A Mark"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...